Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

Université de Montréal

$27,000.00

Characterization of Delay in Diagnosing Latent Autoimmune Diabetes in Adults (LADA) and its Impact on the Well-being and Diabetes Management in the Canadian BETTER Cohort

FY 2024-25

Summary
Diabetes is a chronic condition affecting one in ten people, causing high blood sugar and raising risks for complications like vision loss, kidney failure, and heart disease. It results from impaired insulin action, as in type 2 diabetes (T2D), or insulin deficiency, as in type 1 diabetes (T1D). T1D requires immediate lifelong insulin, while T2D typically involves oral or injectable medications before potentially moving to insulin. In 10% of cases, however, the diagnosis is latent autoimmune diabetes in adults (LADA), or type 1.5 diabetes, which initially resembles T2D but progresses to T1D. Without clear diagnostic guidelines, LADA is often misdiagnosed as T2D, leading to suboptimal treatment and increased risks for complications and anxiety. Diabetes experts have highlighted the importance of expanding research on all aspects of LADA. Our study aims to understand the following questions: Why is LADA diagnosis often delayed? What impact does this delay have on quality of life? How do LADA’s characteristics, treatments, and complications differ from T1D? We will use data from the Canadian BETTER registry, which includes over 4,500 LADA and T1D participants to date with patient reported outcomes containing information on their diabetes history, treatments, complications, and family medical background. We will also conduct semi-structured interviews with LADA patients to explore their diagnostic experiences more in depth and the impact this has had on their quality of life. This is the first study to explore delays in LADA diagnosis and their impact on patients, aiming to improve diagnostic and treatment practices for this condition. We hope this will lead to a better understanding of this condition and improve diagnostic and treatment practices in the future.
Program
Master's Award: Canada Graduate Scholarships
Location
Quebec, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
536580
Name
Nehme Maya
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Characterization of Delay in Diagnosing Latent Autoimmune Diabetes in Adults (LADA) and its Impact on the Well-being and Diabetes Management in the Canadian BETTER Cohort
Programtype2
Studentship Programs
Orgnameinp2
Université de Montréal
Cihramount2
$27,000
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cross-Sectional Analysis; Delay In Diagnosis; Diabetes Complications; Diabetes Heterogeneity; Diabetes Registry; Lada (Latent Autoimmune Diabetes In Adults); Patient Reported Outcomes; Quality Of Life; Semi-Structured Interviews; Type 1 Diabetes
Abstract
Diabetes is a chronic condition affecting one in ten people, causing high blood sugar and raising risks for complications like vision loss, kidney failure, and heart disease. It results from impaired insulin action, as in type 2 diabetes (T2D), or insulin deficiency, as in type 1 diabetes (T1D). T1D requires immediate lifelong insulin, while T2D typically involves oral or injectable medications before potentially moving to insulin. In 10% of cases, however, the diagnosis is latent autoimmune diabetes in adults (LADA), or type 1.5 diabetes, which initially resembles T2D but progresses to T1D. Without clear diagnostic guidelines, LADA is often misdiagnosed as T2D, leading to suboptimal treatment and increased risks for complications and anxiety. Diabetes experts have highlighted the importance of expanding research on all aspects of LADA. Our study aims to understand the following questions: Why is LADA diagnosis often delayed? What impact does this delay have on quality of life? How do LADA’s characteristics, treatments, and complications differ from T1D? We will use data from the Canadian BETTER registry, which includes over 4,500 LADA and T1D participants to date with patient reported outcomes containing information on their diabetes history, treatments, complications, and family medical background. We will also conduct semi-structured interviews with LADA patients to explore their diagnostic experiences more in depth and the impact this has had on their quality of life. This is the first study to explore delays in LADA diagnosis and their impact on patients, aiming to improve diagnostic and treatment practices for this condition. We hope this will lead to a better understanding of this condition and improve diagnostic and treatment practices in the future.
Competitiondate
202412
Approvedterm2
1 yr 0 mth
Pinamesdelim
Nehme, Maya
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $27,000~ $0~